CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase l/ll Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 Antibody (Varlilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02335918
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:28.926900+00:00
Published At: 2019-12-09T00:00:00+00:00
Record Updated At: 2019-12-09
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Squamous Cell Carcinoma of the Head and Neck (SCCHN)", "Ovarian Carcinoma-Enrollment Completed", "Colorectal Cancer (CRC)-Enrollment Completed", "Renal Cell Carcinoma (RCC) (Phase ll Only)", "Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2019-12-09"
protocolSection.identificationModule.nctId: "NCT02335918"
protocolSection.identificationModule.officialTitle: "A Phase l/ll Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 Antibody (Varlilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.